With notable therapies from Biogen, Sarepta and MacroGenics failing to show efficacy in pivotal or confirmatory trials, experts question the use of biomarker evidence for approval while one former ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback